The N+1 Singer Reiterates Buy Rating for Midatech Pharma PLC (MTPH)

The N+1 Singer Reiterates Buy Rating for Midatech Pharma PLC (MTPH)

Separately, Panmure Gordon reiterated a “buy” rating and issued a GBX 297 ($3.82) price objective on shares of Midatech Pharma PLC in a research note on Tuesday, April 4th.

Midatech Pharma PLC (LON:MTPH)‘s stock had its “buy” rating reaffirmed by stock analysts at N+1 Singer in a research report issued on Monday, May 22nd. They currently have a GBX 140 ($1.80) target price on the stock. N+1 Singer’s price objective points to a potential upside of 35.27% from the company’s current price.

About Midatech Pharma PLC Midatech Pharma PLC is an early-stage biopharmaceutical company that focuses on commercializing and developing products in oncology and other therapeutic areas. The Company’s segments include Pipeline Research and Development, and Commercial. The Pipeline Research and Development segment seeks to develop products using the nanomedicine and sustained release technology TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “LSE:MTPH”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Midatech Pharma PLC Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Midatech Pharma PLC and related companies with’s FREE daily email newsletter.

Related posts

Leave a Comment